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Glutamate transporters from the central nervous sys-
tem play a crucial role in the clearance of the transmit-
ter from the synaptic cleft. Glutamate is cotransported
with sodium ions, and the electrogenic translocation
cycle is completed by countertransport of potassium.
Mutants that cannot interact with potassium are only
capable of catalyzing electroneutral exchange. Here we
identify a residue involved in controlling substrate rec-
ognition in the neuronal transporter EAAC-1 that trans-
ports acidic amino acids as well as cysteine. When argi-
nine 447, a residue conserved in all glutamate
transporters, is replaced by cysteine, transport of gluta-
mate or aspartate is abolished, but sodium-dependent
cysteine transport is left intact. Analysis of other substi-
tution mutants shows that the replacement of arginine
rather than the introduced cysteine is responsible for
the observed phenotype. In further contrast to wild
type, acidic amino acids are unable to inhibit cysteine
transport in R447C-EAAC-1, indicating that the selectiv-
ity change is manifested at the binding step. Electro-
physiological analysis shows that in the mutant cys-
teine, transport has become electroneutral, and its
interaction with the countertransported potassium is
impaired. Thus arginine 447 plays a pivotal role in the
sequential interaction of acidic amino acids and potas-
sium with the transporter and, thereby, constitutes one
of the molecular determinants of coupling their fluxes.
Glutamate transporters prevent neurotoxicity by their abil-
ity to maintain low synaptic glutamate concentrations despite
high intracellular glutamate levels in neurons and glia sur-
rounding the cleft (1–5). Moreover, at some synapses glutamate
transporters play an important role in limiting the duration of
synaptic excitation (6–9). They achieve their remarkable con-
centrative power by an electrogenic process (10–12) in which
the transmitter is cotransported with three sodium ions and
a proton (3) followed by countertransport of a potassium ion
(3, 13–15).
One of the five known glutamate transporters, GLT-1, has
been purified from rat brain to near homogeneity and reconsti-
tuted (16, 17). It has been cloned and expressed (18) and is
related to three different glutamate transporters from the cen-
tral nervous system, GLAST-1 (19), EAAC-1 (20), and EAAT-4
(21), as well as to one from the retina (22). Studies of the highly
conserved carboxyl-terminal half of the glutamate transporters
indicate a non-conventional topology containing two reentrant
loops, two transmembrane domains, 7 and 8, long enough to
span the membrane as a-helices as well as an outward facing
hydrophobic linker (23–25). A very recent study arrives at a
somewhat different model including the assignment of trans-
membrane domain 7 as a reentrant loop (26). Two adjacent
amino acid residues of GLT-1 located in transmembrane do-
main 7, tyrosine 403 and glutamate 404, appear to be involved
in potassium binding and are close to one of the sodium binding
sites (15, 27). Because of the sequential nature of the transport
process (13–15), mutations in these residues cause the trans-
porter to be locked in an obligatory exchange mode (15, 27).
Moreover, tyrosine 403 behaves as if it is alternately accessible
to either side of the membrane (28). Analysis of GLT-1 mutants
where serine 440, located in one of the reentrant loops, has
been modified indicates that at least part of this loop is crucial
for the coupling of sodium and glutamate fluxes and that it is
close to the glutamate binding site (29).
We now report on a residue that controls the binding of the
g-carboxyl group of glutamate. Conradt and Stoffel (30) already
noted that arginine 479 of GLAST-1, located in transmembrane
domain 8 (23, 25), is conserved in all dicarboxylic acid trans-
porters of the family but not in the small neutral amino acid
transporter ASCT1 (31, 32), whose substrates have only a
single carboxyl group. They found that mutation of arginine
479 to threonine, which occupies the same position in ASCT-1,
abolishes glutamate uptake, but they noted that there may be
other reasons underlying such a defect (30). Nevertheless the
idea of a role of the arginine in glutamate binding remained
viable, especially after the subsequent cloning and sequencing
of the isotransporter ASCT-2 revealed that it contains a cys-
teine residue at the equivalent position (33, 34). We reason that
mutation of this arginine in a glutamate transporter, which
also transports a non-dicarboxylic acid substrate, might leave
the transport of this substrate intact. It was shown that
EAAT-3, the human homologue of EAAC-1 (35), also exhibits
considerable transport of cysteine (36). We report here that
mutation of the equivalent arginine 447 of EAAC-1 to neutral
or negative amino acid residues completely abolishes transport
of L-glutamate and D- and L-aspartate without impairing cys-
teine transport. Surprisingly, this cysteine transport is electro-
neutral rather than electrogenic. This appears to be due to a
defective interaction with potassium. We propose that arginine
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447, by sequentially participating in the binding of glutamate
and potassium, is enabling the coupling of their fluxes.
EXPERIMENTAL PROCEDURES
Expression of Transporters—Complementary DNAs encoding the
histidine-tagged EAAC-1 and its derived mutants, subcloned in the
oocyte expression vector pOG2 (see below), were linearized with SacI,
and cRNA was transcribed from each of the cDNA constructs with T7
polymerase and capped with 597-methyl guanosine by use of the mMES-
SAGE mMACHINE (Ambion Inc., Austin, TX). Approximately 50 ng of
the various cRNAs was injected into defolliculated stage V-VI Xenopus
laevis oocytes (36), and expression was assayed 3–5 days later by
two-microelectrode voltage clamp recording (15) and/or radiotracer flux
experiments (see below).
Radiotracer Flux Measurements—Uptake of D-[3H]aspartate (10.5
Ci/mmol) and L-[3H]serine (21.7 Ci/mmol) (both from PerkinElmer Life
Sciences) and L-[3H]glutamate (60 Ci/mmol), L-[3H]aspartate (32 Ci/
mmol), and L-[35S]cysteine (1075 Ci/mmol) (all from American Radiola-
beled Chemicals, St. Louis, MO) was performed by placing 5 X. laevis
oocytes per determination in 500 ml of frog Ringer’s solution containing
96 mM NaCl, 2 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2, 5 mM Hepes, pH 7.5,
supplemented with 1 mCi of the radiolabeled amino acids, except for
cysteine, where 10 mCi was used. The amino acids were used carrier-
free unless indicated otherwise. After 20 min at room temperature
(uptake was linear with time for at least 30 min), the oocytes were
washed by passing through 4 wells filled with 1 ml of Ringer’s solution
followed by a 15-min incubation in 10% SDS (500 ml/oocyte). Radioac-
tivity was determined in a Kontron liquid scintillation counter. Each
experiment was performed 3–8 times with different batches of oocytes,
and representative experiments based on five oocytes per determina-
tion are shown.
Voltage Clamp Recording—During two-microelectrode voltage clamp
recording (15), oocytes were perfused with frog Ringer’s solution with
and without amino acid substrates. In experiments where the external
chloride concentration was replaced or varied, equimolar anion substi-
tution was employed, and recordings were made with the bath
grounded via a 3 M KCl/agar bridge connected to a 3 M KCl reservoir
containing an Ag/AgCl electrode. In the figures, records from represent-
ative oocytes (n 5 3–8, at least 2–3 different batches) are presented.
The chloride equilibrium potential was determined by measuring the
reversal potential of endogenous calcium-dependent chloride channels
after activation with A23187 (37).
Radiotracer Flux during Voltage Clamp—Current measurements
were made during superfusion of 30 mM L-[35S]cysteine (2.27 3 1014
cpm/mol) onto oocytes voltage-clamped at 223 mV for 150 s. After
washout of the bath for 1 min, oocytes were transferred to a scintillation
tube, lysed, and measured for radioactivity. Currents induced by
L-[35S]cysteine were recorded using chart software (AD Instruments).
The chloride equilibrium potential measured in two different oocytes of
the batch used was 221 and 223 mV.
Subcloning and Site-directed Mutagenesis—The EAAC-1 cDNA, re-
siding in pBluescript SK2, was generously donated by Dr. Mathias
Hediger. A tail of nine histidines was engineered at its carboxyl using
site-directed mutagenesis using uracil-containing single strand DNA
(38, 39). Briefly, the parent DNA, EAAC-1 or EAAC-1H9 (see below),
was used to transform Escherichia coli CJ236 (dut2, ung2). From one of
the transformants, single-stranded uracil containing DNA was isolated
upon growth in a uridine-containing medium according to the standard
protocol from Stratagene using helper phage R408. This yields the sense
strand, and consequently, the mutagenic primers were designed to be
antisense. Our original intention was to replace the last residue (phe-
nylalanine) by methionine and to add a deca-histidine tail. However
after sequencing throughout the entire coding region from both direc-
tions, it appeared that a single error had occurred, causing a frame-
shift. As a consequence, instead of a tail of 10 histidines, it contained
only 9, and the open reading frame was extended by the sequence
SLEALASQDCHEGPSMRVIS before reaching the new stop codon TAG
(EAAC-1H9). Expression of this transporter in HeLa cells using the
recombinant vaccinia/T7 virus (40) gave rise to identical D-[3H]aspar-
tate transport as the original EAAC-1 cDNA. The EAAC-1H9 construct
served as the parent construct (wild type) for subsequent site-directed
mutagenesis (38, 39), except for the R447C mutant, for which the
original EAAC-1 cDNA served as a parent construct.
The histidine-tagged EAAC-1H9, the original EAAC-1, and the
R447C-EAAC-1 were subcloned into the oocyte expression vector pOG2,
which contained a 59-untranslated Xenopus b-globin sequence and a
39-poly(A) signal, using XhoI and BglII. This causes a reduction of the
39-untranslated region of EAAC-1 from 1621 to 730 base pairs (EAAC-
1H9-pOG2). The mutants were identified by diagnostic restriction sites
and subcloned into the EAAC-1H9-pOG2 constructs using the restric-
tion enzymes AgeI and SpeI. A similar subcloning was also done for the
R447C mutation from the EAAC-1 to the EAAC-1H9 constructs. The
subcloned cDNAs were then sequenced from each direction between
the two restriction sites. In the case of the mutant R447C, which was
the first one prepared for this study, initial characterization of its
properties was carried out by comparing oocytes injected with cRNA
transcribed from R447C-EAAC-1 and EAAC-1 (both without the histi-
dine tail). The features of radiotracer uptake and cysteine currents in
these oocytes were the same as those shown in Figs. 1 and 4 for
EAAC-1H9 and R447C-EAAC-1H9 (therein labeled as R447C). Thus
the R447C mutant does not behave differently because of the presence
of the 20 extra amino acids and the 9 histidines present in EAAC1H9.
RESULTS
Tracer Flux of Amino Acids in the R447C Mutant—X. laevis
oocytes injected with R447C-EAAC-1H9 cRNA exhibit strik-
ingly different transport properties from their counterparts
injected with EAAC-1H9 wild type cRNA (Fig. 1). The mutant
transporters are almost totally defective in the transport of
D-[3H]aspartate, L-[3H]aspartate, and L-[3H]glutamate. All
three acidic amino acids are substrates for the wild type trans-
porter (Fig. 1A). Significantly, R447C transporters are capable
of taking up L-[35S]cysteine, as is the wild type (Fig. 1, A and B).
There is no significant L-[3H]serine uptake in oocytes injected
with wild type cRNA as compared with uninjected oocytes (Fig.
1C), but L-[3H]serine uptake is observed with the R447C mu-
tant (Fig. 1C). Uptake of both L-[3H]serine and L-[35S]cysteine
is fully sodium-dependent (Fig. 1, B and C). Not only are the
acidic amino acids not taken up by the R447C transporters, but
they are unable to bind them. This is exemplified by the inabil-
ity of unlabeled L-aspartate to compete with L-[35S]cysteine
uptake in the mutant (Fig. 2). Whereas the wild type L-[35S]cys-
teine uptake is potently inhibited by 100 mM L-aspartate (4–10-
fold the reported Km for this substrate (20, 35)), L-aspartate
does not inhibit L-[35S]cysteine uptake by the mutant, even at
1 mM (Fig. 2). Similarly, no inhibition of L-[35S]cysteine uptake
in the mutant is observed with L-glutamate or D-aspartate
(data not shown). L-[35S]Cysteine uptake is not inhibited by
nonrelated compounds like g-aminobutyric acid, neither in the
mutant nor in the wild type (Fig. 2). The data presented in Fig.
2 also indicate that the mutant has a higher affinity for cys-
teine than the wild type, and the same phenomenon is observed
with serine (Fig. 2). That this is indeed the case is seen from the
apparent Km values, measured as the ability to induce steady
state currents (see “Electrophysiological Characterization of
the R447C Mutant” below).
Tracer Flux in Other Substitution Mutants at Position 447—
The inability of the R447C mutant to interact with acidic amino
acids is caused by the removal of the arginine rather than the
introduction of a cysteine at this position. Mutants in which
arginine 447 has been replaced by glutamate (R447E), lysine
(R447K), glycine (R447G), and serine (R447S), retain the abil-
ity to take up L-[35S]cysteine, although it is reduced in R447K
(Fig. 3A). In contrast, none of them, with the exception of
R447K, is able to transport D-[3H]aspartate (Fig. 3B). However,
even though in R447K transporters the positive charge at this
position is maintained, these mutant transporters exhibit a
markedly reduced uptake of this acidic amino acid (Fig. 3B).
The absence of the positive charge at position 447 is correlated
with the ability to exhibit significant L-[3H]serine transport;
this is observed with all mutants except R447K (Fig. 3C). We
have tried to restore D-[3H]aspartate transport to R447C using
the positively charged sulfhydryl reagents (2-aminoethyl)-
methane thiosulfonate (2.5 mM), which would be expected to
introduce a lysine-like structure at this position, and [(2-tri-
methylammonium)ethyl] methane thiosulfonate (10 mM). No
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effects on the transport of any of the substrates was observed
after 5-min preincubations of oocytes expressing R447C with
these reagents or the negatively charged (2-sulfonatoethyl)
methane thiosulfonate (10 mM) (data not shown).
Electrophysiological Characterization of the R447C Mu-
tant—Uptake of excitatory amino acids by all glutamate trans-
porter clones thus far characterized results in the activation of
a current reflecting the sum of the inward current (resulting
from cotransport of coupled ions such as sodium) together with
a chloride current flowing through a thermodynamically un-
coupled conductance pathway (21, 37). The voltage dependence
of the currents mediated by wild type EAAC-1H9 and its mu-
tant R447C has been determined by clamping oocytes express-
ing the transporters at potentials between 2100 and 140 mV
(increments of 20 mV) in the presence and absence of the
substrates D-aspartate and L-cysteine. In the wild type EAAC-
1H9, steady state D-aspartate (Fig. 4A) and L-cysteine currents
(Fig. 4D) are observed that reverse at potentials greater than
130 mV (Fig. 4, C and F). The behavior of R447C is quite
different. No significant currents are observed with D-aspartate
(Fig. 4B) and L-glutamate and L-aspartate (data not shown),
consistent with the inability of R447C transporters to take up
acidic amino acids (Figs. 1A and 3B). With L-cysteine, transport
currents are observed (Fig. 4E), but the L-cysteine currents of
R447C exhibit a reversal potential around 225 mV, similar to
the chloride equilibrium potential (Fig. 4F). The apparent Km
value for cysteine was 27.9 6 7.9 mM for the R447C-EAAC-1H9
mutant (measured at 120 mV, n 5 3) and 110 6 24 mM for the
wild type (measured at 280 mV, n 5 3). The corresponding
values for serine- and alanine-induced currents in the mutant
were 13.9 6 4.1 and 17.9 6 3.1 mM, respectively (n 5 3). In the
wild type, 1 mM each of the latter two amino acids induced very
small currents (,10% of those with D-aspartate), consistent
with the very low affinities observed with its human EAAT-3
homologue (36).
In addition to the steady state current, a transient cysteine-
induced current is observed with R447C (Fig. 4E). This tran-
sient current appears to be capacitative, because the charge
movements, estimated by subtraction of the steady state cur-
rents, after following hyperpolarizing or depolarizing pulses
are equal to those following the return to the original potential
FIG. 1. Uptake of acidic amino acids, cysteine, and serine by
oocytes expressing wild type EAAC-1H9 and mutant R447C. Up-
take was performed using carrier-free D-[3H]aspartate (190.4 nM),
L-[3H]aspartate (62.5 nM), L-[3H]aspartate (62.5 nM), L-[3H]glutamate
(33.3 nM), L-[35S]cysteine (18.6 nM), and L-[3H]serine (92.2 nM) is de-
scribed under “Experimental Procedures.” In the experiment depicted
in A, values obtained with uninjected oocytes (control) are subtracted,
and in those shown in B and C, unsubtracted values are given. A, the
transport rates for the R447C mutant are given as the percentage of the
rates of the wild type (wt). In the experiment depicted in A, the wild
type rates (mean 6 S.E.) were (fmol/oocyte/min): D-[3H]aspartate,
54.1 6 6.2; L-[3H]aspartate, 6.8 6 0.7; L-[3H]glutamate, 5.2 6 0.6;
L-[35S]cysteine, 1.68 6 0.41. In B and C, rates have been determined in
the presence (open bars) or absence (hatched bars) of sodium (choline
substitution). The large differences in rates are due to the differences in
concentrations and apparent Km values of the various substrates (20,
35, 36).
FIG. 2. Effect of unlabeled amino acids on uptake of L-[35S]cys-
teine in wild type and R447C. Uptake of L-[35S]cysteine (10 mCi, 25
mM final concentration) was measured in the presence of the unlabeled
amino acids at the indicated concentrations in oocytes injected with the
wild type or R447C transporter cRNAs. Values obtained with unin-
jected oocytes have been subtracted. Values are given as percent of
control (no additions). The control values were 1.11 6 0.12 and 1.40 6
0.15 pmol/oocyte/min for wild type and R447C mutant, respectively.
GABA, g-aminobutyric acid.
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(Fig. 5). Neither steady state nor transient cysteine currents
were observed in the absence of sodium (lithium or choline
substitution) and also not in uninjected oocytes (data not
shown). Similar observations have been made on oocytes in-
jected with R447E-EAAC-1H9 cRNA, although the outward
currents are smaller than when cysteine occupies this position
(data not shown). Varying [Cl2]o shifted the reversal potential
of R447C by 48 mV/10-fold change in [Cl2]o (Fig. 6). Further-
more, in R447C, substitution of Cl2 by gluconate in the Ring-
er’s solution bathing the oocytes abolishes the outward current
at positive potentials up to 170 mV (data not shown). These
observations suggest that in R447C, Cl2 ions carry the major
part of the current activated by L-cysteine superfusion.
The selective loss of the ability of the R447C mutant to
catalyze the inwardly rectifying electrogenic transport current
(Fig. 4E) indicates that the uptake of L-[35S]cysteine is electro-
neutral rather than the electrogenic process observed with the
wild type. Evidence supporting this idea is presented in Fig. 7.
Oocytes expressing wild type EAAC-1 or R447C were voltage-
clamped at 223 mV, near the equilibrium potential of chloride,
and superfused with 30 mM L-[35S]cysteine. This non-saturating
concentration, around the apparent Km for cysteine, was used
to enable the uptake measurements without having to add
excessive amounts of radiolabel. Currents recorded simulta-
neously during radiolabeled uptake are dramatically different
between the two groups of cells (Fig. 7). Although uptake of
L-[35S]cysteine in the two groups is similar, an electrogenic
uptake current is only observed in wild type EAAC-1 (Fig. 7A)
but not in the mutant (Fig. 7B).
The behavior of R447C is reminiscent of that of mutants
E404D (15) and Y403F (27) of the glutamate transporter
GLT-1. They are locked in the electroneutral exchange mode
because they cannot interact with potassium, which is required
for the return of the unloaded transporter. We have previously
used reconstitution of solubilized membrane proteins from
HeLa cells expressing wild type GLT-1, E404D, and Y403F to
show that D-[3H]aspartate uptake is defective with internal
potassium (net flux) but not with unlabeled glutamate or as-
partate (exchange) on the inside (15, 27). HeLa cells exhibit a
very high endogeneous L-[35S]cysteine transport, and transfec-
tion with wild type EAAC-1H9 does not elevate it significantly.
We therefore tried to purify EAAC-1H9 from the cysteine
transporters endogeneous to the HeLa cells on Ni21-nitrilotri-
acetic acid beads. However, with several detergents we tried,
inactivation was so rapid that no reconstitutable transport
could be recovered after elution of the beads with imidazole.
Therefore, we used an alternative approach to probe the inter-
action of potassium with wild type and R447C transporters. In
oocytes, which have high concentrations of endogenous sub-
strates (35, 41), elevation of external potassium induces re-
verse transport (13, 15, 42). This also results in the activation
of the transporter-mediated anion conductance, readily ob-
served when highly permeant anions, such as nitrate or thio-
cyanate, are present (15). This anion conductance is not acti-
vated by external potassium in the E404D mutant (15). In the
presence of 38 mM thiocyanate, potassium induces an outward
current at positive potentials in wild type EAAC-1H9 (Fig. 8A).
Amino acid substrates can also induce the transporter-medi-
ated anion conductance (37). In the thiocyanate supplemented
medium, cysteine induces currents of similar size as potassium
(Fig. 8A). Neither cysteine- nor potassium-dependent anion
currents are observed in uninjected oocytes (data not shown).
In contrast to the wild type, potassium is not able to induce
these currents in the mutant (Fig. 8). This is not due to a
defective anion conductance per se, because cysteine induces
anion currents in R447C that are even larger than those in the
wild type (Fig. 8B).
DISCUSSION
Our results indicate that arginine 447 plays a key role in
recognition of the g-carboxyl group of the anionic transporter
substrates. Substitution of this arginine by many other resi-
dues eliminated the ability to transport the acidic amino acid
substrates L-glutamate and D- and L-aspartate (Figs. 1A and
3B) without effect on cysteine transport (Figs. 1, A and B, and
3A). Furthermore, competition experiments indicate that the
acidic amino acids cannot even bind to R447C transporters
(Fig. 2), and similar results have been obtained with R447E
transporters (data not shown). Only when another positively
charged amino acid residue replaces arginine 447 is a low level
transport of acidic amino acids retained (Fig. 3B). Thus the
requirement for just the positive charge at this position is not
enough for optimal transport.
The simplest and most straightforward explanation for these
observations is that the guanidinium group of arginine 447
directly interacts with the g-carboxyl group of L-glutamate. In
the absence of a crystal structure of any cotransporter, it is
impossible to rule out indirect effects. However, a long range
conformational change caused by replacing arginine would
need to be as subtle as to impede amino acids to bind to a
FIG. 3. Uptake of L-cysteine, D-aspartate, and L-serine by sub-
stitution mutants at position 447. Uptake of L-[35S]cysteine,
D-[3H]aspartate, and L-[3H]serine (all carrier-free) was performed as
described in Fig. 1. The values are corrected for those obtained with
uninjected oocytes and are given as percent of wild type (wt, A and B) or
R447C (C) uptake. The control uptake rates (fmol/oocyte/min) were:
L-cysteine, wild type, 0.67 6 0.06; D-aspartate, wild type, 52.0 6 3.9;
L-serine, R447C, 22.1 6 4.9.
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distant site, while leaving cysteine binding intact. It is of in-
terest to note that diffraction studies of the crystallized ligand
binding domain of the glutamate receptor GluR2 show directly
that one of the two carboxyls of the glutamate analogue kainate
is liganded by arginine (43). Also in two recent studies on
bacterial multidrug-resistant transporters, a critical electro-
static interaction in substrate binding has been inferred (44,
45).
The apparent lack of reactivity of the cysteine, introduced at
position 447, with methane thiosulfonate reagents indicates
that this residue may not have an unrestricted accessibility to
small molecules. This is perhaps not unexpected and may in
fact be one of the manifestations of the substrate specificity of
the transporter. For instance, binding of some parts of the
glutamate molecule such as the a-amino and a-carboxyl
groups, could induce a conformational change, exposing argi-
nine 447. Even in the absence of an “induced fit” type of mech-
anism, it should be kept in mind that the side chain of cysteine
is shorter than that of arginine. If the guanidinium group of
arginine would be at a water-accessible surface, the sulfhydryl
group of the introduced cysteine would be below it.
The presence of an arginine at position 447 is not only im-
portant for the interaction of EAAC-1 with acidic amino acids,
it also hinders the interaction of the transporter with small
neutral amino acids. Very little if any uptake of L-[3H]serine is
observed in wild type, but highly significant activity is observed
FIG. 4. Currents mediated by wild
type (wt) and R447C transporters.
Subtracted records showing currents in-
duced by D-aspartate (A and B) and L-
cysteine (D and E) of representative oo-
cytes expressing EAAC-1H9 wild type (A
and D) and R447C (B and E). Currents
recorded in the absence of substrate dur-
ing 250 ms voltage pulses from 2100 to
140 mV were subtracted form those dur-
ing superfusion of 1 mM D-aspartate or
L-cysteine. The prepulse potential was
230 mV. Voltage dependence of steady
state currents taken at 200 ms induced by
D-aspartate (C) or L-cysteine (F) is shown
in wild type (squares) and R447C mutant
(circles).
FIG. 5. Voltage dependence of
charge movement by the R447C
transporter. A, family of currents in-
duced by application of 30 mM cysteine
with 600-ms voltage pulses between 180
and 2140 mV in 20-mV increments. The
holding potential was 230 mV. B, the
charge movements were calculated by in-
tegrating the currents after subtraction of
the steady state component as described
in Wadiche et al. (12). The on and off
charge movements were equal, and simi-
lar results were seen in nine other cells.
FIG. 6. Dependence of the reversal potential of steady state
cysteine currents by R447C transporters. Currents induced by 1
mM cysteine with 250-ms voltage pulses between 180 and 2120 mV
were recorded in oocytes expressing R447C transporters (n 5 3) using
perfusion media of varying chloride concentrations (gluconate substitu-
tion). The error bars (S.E.) are smaller than the size of the symbols. The
dashed line gives the predicted chloride dependence of the reversed
potential for the mutant according to the Nernst equation for chloride.
FIG. 7. Comparison of transport currents and radioactive up-
take in wild type (wt) and R447C transporters. Oocytes expressing
wild type (A), R447C (B), and uninjected oocytes were clamped at 223
mV, and currents induced by 30 mM L-[35S]cysteine were recorded.
Oocytes were washed, and radioactive cysteine taken up was deter-
mined by scintillation counting.
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in many of the substitution mutants at this position (Figs. 1C
and 3C). The same is true for L-[3H]alanine uptake (data not
shown). Moreover, in contrast with the wild type, both tran-
sient currents and steady state anion currents in R447C are
also induced by serine, alanine, threonine, and glutamine (data
not shown). Thus, the substrate specificity of R447C-EAAC-
1H9 is very reminiscent of that of ASCT-2, where a cysteine
residue occupies the corresponding position (33, 34). It is of
interest to mention that recently a bacterial family member
capable of transporting serine has been cloned (46). Instead of
an arginine at this position it contains a glutamate residue,
and this is in nice agreement with the strongly enhanced serine
transport observed in the R447E-EAAC-1 mutant (Fig. 3C).
One of the striking findings of this study is that in oocytes
expressing R447C-EAAC-1H9, L-[35S]cysteine uptake is un-
hampered but, unlike the wild type, this uptake is electroneu-
tral (Figs. 4 and 7). This could be due to a change in stoichi-
ometry, allowing net flux to proceed in an electroneutral
fashion. Alternatively, L-[35S]cysteine uptake in the mutant
may represent obligatory exchange. This is certainly feasible
since it has been shown (41) that oocytes contain 1.2 mM inter-
nal ASCT-1 substrates (alanine, cysteine, threonine, and ser-
ine). In the case of GLT-1, where we could use a reconstitution
approach, allowing control of the medium composition from
both sides of the membrane, we have shown that two mutants,
E404D and Y403F, which cannot interact with potassium from
either side of the membrane, are locked in an obligatory ex-
change mode (15, 27). This is because electrogenic glutamate,
and probably also cysteine, uptake by their transporters con-
sists of two sequential translocation steps: 1) translocation of
sodium and glutamate and 2) translocation of potassium in the
opposite direction (13–15). Exchange represents a partial reac-
tion of the full cycle, namely reversible translocation of sodium
and the amino acid substrate, which can also take place in the
absence of potassium (13, 14) or in mutants with defective
potassium interactions (15, 27). In the case of EAAC-1, we can
directly monitor only its interaction with external potassium
(Fig. 8A). In the R447C mutant this interaction is impaired
(Fig. 8B). It seems therefore likely that R447C-EAAC-1H9, just
like GLT-1-E404D (15) and GLT-1-Y403F (27), is locked in an
obligatory exchange mode because of its defective interaction
with potassium.
In contrast to the wild type, cysteine induces outward cur-
rents in R447C-EAAC-1H9 (Fig. 4E), which are mainly carried
by chloride. The ability of the mutant to mediate gating of the
anion conductance mediated by amino acid substrates is con-
sistent with observations that this activity is observed in
GLT-1 mutants locked in the exchange mode (15, 27). Electro-
neutral cysteine transport mediated by the R447C mutant is
accompanied by slow transient currents (Figs. 4, E and 5).
These may reflect the reversible movement of sodium and
substrates across the electric field, which would give rise to
capacitative currents and is also consistent with the idea that
cysteine transport in R447C is electroneutral because it is
operating as an exchanger. The transient currents are not
observed in the wild type because it catalyzes net flux, mani-
fested as a resistive current. The substitution mutants of argi-
nine 447 render EAAC-1 similar to ASCT in one more aspect;
also, ASCT-1 has been shown to be an obligate exchanger, and
induction of this exchange activates an anion conductance (41).
R447C appears to display larger outward currents with NaSCN
at positive potentials than wild type (Fig. 8). If gating of the
anion conductance would be associated with the cysteine-bound
form of the transporter rather than the potassium-bound form,
the mutant would be expected to exhibit a larger anion con-
ductance than the wild type.
How could mutation of a single arginine residue of EAAC-1
impair both glutamate binding and the interaction of the trans-
porter with potassium? An attractive possibility would be that
arginine 447 can form alternate ion pairs with the transported
acidic amino acid and an acidic residue of the transporter itself.
The intramolecular salt bridge would somehow be important
for the interaction with potassium or its translocation. EAAC-1
has several acidic amino acid residues that could be candidate
partners, including glutamate 374, which occupies the same
position as glutamate 404 of GLT-1. Further work will be
required before this possibility can be tested directly. There
still is some controversy on the membrane topology of the
glutamate transporters (23–26), and no information on the
proximity of its transmembrane domains is available now. Ap-
proaches, pioneered by Kaback and co-workers (see Ref. 47) to
determine proximity relationships in lactose permease, will be
important to determine if arginine 447 is close to glutamate
374.
The central finding of this study is that arginine 447 controls
substrate binding as well as the interaction of potassium with
the transporter. Although it has been shown that in chimeric
bacterial cotransporters the selectivity of the ion depends on
the nature of the substrate cotransported (48), we have shown
here that mutation of a single residue affects separate trans-
location steps. Regardless of the precise mechanism by which
mutation of arginine 447 influences potassium and substrate
selectivity, the results suggest the existence of a common bind-
ing pocket for countertransported solutes. The results further
suggest a plausible countertransport mechanism involving a
competitive and sequential binding of substrate and potassium.
This may be a widespread principle applying to other counter-
transporters as well, as has recently been suggested for the
multidrug transporter EmrE in which glutamate 14 sequen-
tially binds substrates and protons in a mutually exclusive
FIG. 8. Voltage dependence of steady state anion currents of
wild type and R447C transporters. Voltage dependence of sub-
tracted records obtained by subtracting currents recorded in 58 mM
NaCl, 38 mM NaSCN,2 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2, 5 mM
Hepes, pH 7.5, from those in a similar solution with 38 mM KSCN
instead of NaSCN (squares) or currents in the NaSCN containing me-
dium subtracted from those in the same medium supplemented with 1
mM cysteine (triangles). The voltage pulses were for 250 ms from 260 to
140 mV, and the prepulse potential was 230 mV. Values recorded after
200 ms were taken as steady state values. A, wild type; B, R447C.
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fashion, providing a molecular basis of cationic drug/H1 anti-
port (49).
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